Ibogaine is a plant-derived alkaloid found in the shrub Tabernanthe iboga. Online, it is sometimes presented as a “breakthrough” or even a “revolution” in addiction treatment, especially in relation to opioid dependence. It is important, however, to separate marketing language from current clinical knowledge and from the real standards of addiction care.

Legal Status and Medical Context

Ibogaine is not approved in Poland as a medication and is not a standard treatment method for addiction. In some countries, experimental research is being conducted, but this does not make ibogaine part of routine clinical practice. Its use is associated with significant physical and psychiatric risks.

At Zeus Detox & Rehab, we do not provide ibogaine-based therapy or treatment with other psychedelic substances. Addiction treatment is based on medical qualification, stabilisation of health status, and therapy delivered in a controlled clinical setting. Our treatment model is described on the page drug addiction treatment.

How Ibogaine Works

Ibogaine affects multiple neurotransmitter systems, including dopaminergic, serotonergic, and glutamatergic pathways. It alters perception, intensifies introspective processes, and may induce powerful psychological experiences. Some reports suggest that it may reduce opioid withdrawal symptoms, but these mechanisms are not fully understood and do not provide a basis for treating it as a standard form of care.

The experience after ibogaine may be prolonged and physically demanding. It may involve altered consciousness, disturbances of orientation, mood fluctuations, and physical symptoms.

Risks Associated with Ibogaine Use

Ibogaine may cause cardiac rhythm disturbances, prolongation of the QT interval on ECG, electrolyte imbalance, and neurological complications. The literature includes reports of serious cardiac events, including deaths, especially in people with unrecognised cardiovascular disease.

The risk increases in cases of self-administration, absence of medical qualification, mixing with other substances, and in individuals with a history of mental health disorders.

Ibogaine and Opioid Addiction

Ibogaine most often appears in discussions about opioid addiction treatment. The high search volume around the topic reflects a strong desire for rapid interruption of withdrawal symptoms. It must be clearly stated, however, that addiction is a chronic disorder, and reducing withdrawal symptoms is not the same as treating relapse mechanisms.

A safe opioid withdrawal process should take place under medical supervision. The appropriate stabilisation stage is described on the page drug detox.

Why a “Revolution” Does Not Replace Treatment Structure

Claims about a breakthrough or a revolution often refer to individual experiences or early-stage research. Addiction treatment, however, requires a comprehensive approach that includes medical stabilisation, therapy, work on triggers, and a relapse prevention plan. A one-time pharmacological intervention, even if it reduces symptoms, does not replace the therapeutic process.

The therapy stage delivered in a clinical setting is described on the page drug addiction therapy.

When Medical Help Is Necessary

Urgent medical help is necessary in the event of cardiac rhythm disturbances, loss of consciousness, seizures, severe agitation, symptoms of psychosis, or significant chest symptoms after the use of psychoactive substances. Equally important warning signs include severe withdrawal syndrome and loss of control over opioid use.

In such situations, the priority is safety and medical qualification, not experimentation with unverified methods.